Cargando…

Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation

INTRODUCTION: De novo C3 glomerulonephritis (C3GN) after transplant is uncommon. Although eculizumab has been used successfully in several cases, the response is heterogeneous, and treatment strategies remain undefined. The use of repository corticotropin in C3GN has not been described in the litera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naseer, Muhammad Saad, Singh, Ayush, Singh, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670034/ https://www.ncbi.nlm.nih.gov/pubmed/36751532 http://dx.doi.org/10.1159/000520387

Ejemplares similares

Treatment of fibrillary glomerulonephritis with use of repository corticotropin injections
por: Maroz, Natallia, et al.
Publicado: (2018)

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

Post-transplant de-novo renal phospholipidosis in a kidney transplant recipient: Fabry disease or something else?
por: Naseer, Muhammad Saad, et al.
Publicado: (2020)

Recurrent and de novo Glomerulonephritis After Kidney Transplantation
por: Lim, Wai H., et al.
Publicado: (2019)

Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
por: Patel, Aarat, et al.
Publicado: (2016)

Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin
por: Hartung, Daniel M., et al.
Publicado: (2018)

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies
por: Fischer, Peter A, et al.
Publicado: (2018)

Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection
por: Anesi, Stephen D., et al.
Publicado: (2021)

Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
por: Mirsaeidi, Mehdi, et al.
Publicado: (2022)

Subcutaneous repository corticotropin gel for non-infectious panuveitis: Reappraisal of an old pharmacologic agent
por: Agarwal, Aniruddha, et al.
Publicado: (2016)

Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
por: Knight, Tyler, et al.
Publicado: (2017)

Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series
por: Brown, Alan N
Publicado: (2016)

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis
por: Hunter, Samuel F, et al.
Publicado: (2021)

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review
por: Girman, Cynthia, et al.
Publicado: (2022)

De Novo Fibrillary Glomerulonephritis (FGN) in a Renal Transplant with Chronic Hepatitis C
por: Filippone, Edward J., et al.
Publicado: (2013)

Use of Repository Corticotropin Gel (Acthar) in Progressive Nephrotic Syndrome Secondary to Transplant Glomerulopathy: A Report of Three Cases
por: Markell, Mariana, et al.
Publicado: (2019)

De novo lupus-like glomerulonephritis after pediatric non-kidney organ transplantation
por: Farkas-Skiles, Cristina M., et al.
Publicado: (2021)

Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records
por: Chopra, Ishveen, et al.
Publicado: (2019)

Repository Corticotropin Injections Promote Clinical Remission and Regulatory T Cell Expansion in Membranous Nephropathy
por: Hartzell, Susan, et al.
Publicado: (2021)

The Association Between Post–Kidney Transplant De Novo Glomerulonephritis and Alloimmunity
por: Khairallah, Pascale, et al.
Publicado: (2021)

H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes
por: Kutz, Christen
Publicado: (2016)

Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone
por: Lal, Ritu, et al.
Publicado: (2015)

Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
por: Ho-Mahler, Nancy, et al.
Publicado: (2020)

Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2022)

Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis
por: Bindra, Jas, et al.
Publicado: (2021)

Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection
por: Hayes, Kyle, et al.
Publicado: (2021)

A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse
por: Kaplan, Jeffrey, et al.
Publicado: (2020)

Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2022)

Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States
por: Nelson, Winnie W., et al.
Publicado: (2019)

Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
por: Gold, Laura S, et al.
Publicado: (2019)

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
por: Fleischmann, Roy, et al.
Publicado: (2020)

Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis
por: Rice, J. Bradford, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH(1‐24) Depot and Methylprednisolone in Healthy Subjects
por: Poola, Nagaraju, et al.
Publicado: (2021)

A Randomized Prospective Trial Comparing Repository Corticotropin Injection and Intravenous Methylprednisolone for Neuroprotection in Acute Optic Neuritis
por: Bennett, Jeffrey L., et al.
Publicado: (2023)

Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept
por: Decker, Dima A., et al.
Publicado: (2020)

Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
por: Hayes, Kyle, et al.
Publicado: (2020)

Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis
por: Wan, George J, et al.
Publicado: (2020)

Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis
por: Hayes, Kyle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p50964gf1q8roegvu5u4bqinqr